Rubio, Warren to introduce pharmaceutical supply chain review measure: report

Two U.S. senators want a review of the U.S. drug manufacturing industry, claiming that the ongoing coronavirus pandemic exposed a dependence on drugs manufactured in China and other countries.

Reuters reported Tuesday that Sens. Marco RubioMarco Antonio RubioSenators will have access to intelligence on Russian bounties on US troops Overnight Defense: Lawmakers demand answers on reported Russian bounties for US troops deaths in Afghanistan | Defense bill amendments target Germany withdrawal, Pentagon program giving weapons to police The Memo: GOP cringes at new Trump race controversy MORE (R-Fla.) and Elizabeth WarrenElizabeth WarrenPolitical establishment takes a hit as chaos reigns supreme Supreme Court rules consumer bureau director can be fired at will Juan Williams: Time for boldness from Biden MORE (D-Mass.) will introduce a bipartisan bill Tuesday that would establish a study on the effects of the U.S.’s reliance on foreign companies when it comes to acquiring necessary medicines.

Rubio told the news service that the bill would provide lawmakers the information necessary to address inefficiencies in the U.S. supply chain.

“To defeat the current COVID-19 crisis and better equip the United States against future pandemics, we must take control of our supply chain and rely less on foreign countries for our critical drugs,” added Warren in a statement to the news service.

Gilead Sciences, the U.S. company behind the manufacturing of antiviral drug Remdesivir, announced this week that it would price vials of the drug at nearly $400 per dose, equating about $2,340 for a typical 5-day treatment plan. The announcement caused a flurry of outrage from advocates of lowering prescription drug prices, who argued that taxpayers already helped fund the drug’s development.

“As a company, Gilead is now worth over $15 billion more than before the pandemic, in part because it expects to make enormous profits by charging over $3,000 for a drug they had already developed years ago,” Sen. Bernie SandersBernie SandersPolitical establishment takes a hit as chaos reigns supreme Twitch temporarily suspends Trump account over ‘hateful conduct’ Juan Williams: Time for boldness from Biden MORE (I-Vt.) tweeted. “Their greed must be stopped.”

As a company, Gilead is now worth over $15 billion more than before the pandemic, in part because it expects to make enormous profits by charging over $3,000 for a drug they had already developed years ago.

Their greed must be stopped.https://t.co/v6aoZi9tb5

— Bernie Sanders (@BernieSanders) June 29, 2020 .